home / stock / arch:cc / arch:cc news

ARCH:CC News and Press, Arch Biopartners Inc.

Stock Information
Company Name: Arch Biopartners Inc.
Stock Symbol: ARCH:CC
Market: TSXVC
Website: archbiopartners.com
Menu
ARCH:CC ARCH:CC Quote ARCH:CC Short ARCH:CC News ARCH:CC Articles ARCH:CC Message Board
Get ARCH:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
ARCH:CC - Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilast...
ARCH:CC - Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial ...

ARCH:CC - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II tria...

ARCH:CC - UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pa...
ARCH:CC - Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevent...

ARCH:CC - Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus Phase II findings previously disclosed support dipeptidas...

ARCH:CC - University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial...
ARCH:CC - Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the preven...

ARCH:CC - Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug Administration (...

ARCH:CC - Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting...
Next 10